April 2026 digest

Pediatric Atopic Dermatitis Guidelines in 2026:
Convergence of Evidence, Divergence of Practice

The recent JAAD 2026 guidelines on pediatric atopic dermatitis DOI: 10.1016/j.jaad.2026.02.114, led by the late Robert Sidbury, marks an important milestone: it is the first fully evidence-graded, pediatric-specific update in the era of biologics and JAK inhibitors. Built on a strict GRADE methodology and largely restricted to randomized controlled trials, it delivers 27 recommendations covering topical, phototherapy, and systemic treatments.

What is striking is not only the breadth of therapies now endorsed—from moisturizers and topical corticosteroids to dupilumab, IL-13 blockers, IL-31 blockade, and oral JAK inhibitors—but also the normalization of a proactive, maintenance-oriented strategy, including intermittent use of topical corticosteroids and calcineurin inhibitors.

Yet, when viewed from an epistemological perspective, this document also highlights a divergence in how the concepts underpinning guidelines are constructed in dermatology.

The U.S. approach, exemplified by the JAAD guideline, is highly structured, evidence-driven, and therapeutics-centered. It privileges randomized trials, regulatory approvals, and clearly graded recommendations. This produces clarity and authority—but at the cost of narrowing the field to what is measurable within clinical trials. The guideline itself acknowledges this limitation, noting the frequent reliance on off-label use in pediatric practice due to gaps in formal evidence.

By contrast, European guidelines (EuroGuiDerm, DOI: 10.1111/jdv.20639) and, to some extent, Japanese recommendations (DOI: 10.1016/j.alit.2025.01.003) adopt a broader clinical lens. They integrate not only pharmacologic efficacy but also patient education, access to care, treatment burden, and long-term self-management strategies. Traditional approaches such as wet wraps, structured skin care, and contextualized therapeutic choices retain a more visible role, with serial SCORAD severity assessments central to decision-making. In Japan, the framework remains explicitly oriented toward induction of remission followed by long-term control, with regional therapeutic specificities such as the early inclusion of delgocitinib and nemolizumab in the therapeutic armamentarium.

These differences are not merely geographic—they reflect distinct ways of producing knowledge in medicine. One model is evidence-hierarchical, prioritizing randomized controlled trials and regulatory validation. The other is more practice-integrated, embedding evidence within patient experience, health system constraints, and real-world clinical decision-making. Atopic dermatitis, perhaps more than any other inflammatory disease, sits at the intersection of these two paradigms.

The current convergence around targeted therapies suggests that global dermatology is entering a shared therapeutic era. However, the persistence of these complementary frameworks reminds us that treatment is not only about molecules, but also about models of care.

In a Nutshell

---

#StayInformed: